Opinion|Videos|April 14, 2025
Role of Rebiopsy at Disease Progression in EGFRm NSCLC
Panelists discuss how second-line therapy after osimertinib monotherapy depends on resistance mechanisms. If MET amplification, consider MET inhibitors plus EGFR tyrosine kinase inhibitors (TKIs). For C797S mutation, potential options include first- or third-generation EGFR TKI combinations. Chemotherapy remains a key fallback.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Regarding treatment sequencing, how do you approach second-line therapy after osimertinib monotherapy?
Advertisement
Related to this article
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Roswell Park Comprehensive Cancer Center unveiled a new and more compact mobile lung cancer screening unit.
The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
Udai S. Kammula, MD, FACS, discusses TIL therapy outcomes, the UMIS biomarker, and treatment implications in metastatic uveal melanoma.
CHMP has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma
3
Phase 1 Data Support DAWN-303’s Evaluation of INCB161734 in Frontline KRAS G12D–Mutated PDAC
4
Tumor-Reactive TIL and UMIS Biomarker Predict Response in Metastatic Uveal Melanoma
5